Aurinia Presents Data Demonstrating LUPKYNIS™ (voclosporin) Efficacy Across Lupus Nephritis Biopsy Classes at National Kidney Foundation 2021 Spring Clinical Meetings Apr 8, 2021
Aurinia Announces Positive Cost-Effectiveness Assessment of LUPKYNIS™ (voclosporin) in Latest ICER Draft Evidence Report Mar 15, 2021
Aurinia Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Operational Highlights Feb 24, 2021
Aurinia Pharmaceuticals to Present at the SVB Leerink 10th Annual Global Healthcare Conference Feb 18, 2021
Aurinia Pharmaceuticals to Release Fourth Quarter and Year End 2020 Financial Results on February 24, 2021 Feb 17, 2021
FDA Approves Aurinia Pharmaceuticals’ LUPKYNIS™ (voclosporin) for Adult Patients with Active Lupus Nephritis Jan 22, 2021
Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan Dec 17, 2020
Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity Dec 15, 2020
